Mohammed Dyna Jaza, Jalal Sana Dlawar, Yassin Ahmed Khudair, Mohammed Ali Ibrahim, Al-Allawi Nasir Abdulsalam
Department of Hematology, Hewa Hemato-onology Hospital, Sulaimani, Iraq.
Department of Pathology, College of Medicine, University of Sulaimani, Sulaimani, Iraq.
Indian J Hematol Blood Transfus. 2021 Apr;37(2):264-270. doi: 10.1007/s12288-020-01345-1. Epub 2020 Sep 3.
While many studies addressed the outcome of adult ALL in developed Western countries, there is paucity of such prospective studies from developing Mediterranean ones. This is a prospective cohort study conducted at Hiwa Cancer Hospital in Sulaimani city and Nanakali Hospital in Erbil city-Kurdistan Iraq from March 2012 to August 2017. The main characteristics of adult ALL patients, type of therapy and risk factors were analyzed to assess their impact on treatment outcome and survival status. A total of 109 adult ALL patients were included with a median age of 24 years and male to female ratio of 1.7:1. B-ALL accounted for 76.1% of the cases, while the rest were T-ALL. BCR-ABL rearrangement was encountered in 12% of B-ALL. Complete remission (CR) rate was 81.7%, the overall 5 year survival (OS) was 38%, Relapse Free 5 year Survival (RFS) was 49%. Younger adults (< 35 years) had significantly higher CR rates and OS compared to the older group ( < 0.001 each). On the other hand, gender, high leucocyte count ≥ 50×10/L, immunophenotype (including B and T ALL subtypes), and clinical risk status did not predict a poor outcome. Multivariate analysis revealed that only age < 35 years and BCR-ABL rearrangement were significantly associated with better OS. Despite some limitations, the outcomes of Iraqi adult ALL is comparable to those reported in Western developed countries, with particularly favorable outcomes in younger patients. The need to improve outcome in adult ALL remains an important priority in our country as it is throughout the world.
虽然许多研究探讨了西方发达国家成人急性淋巴细胞白血病(ALL)的治疗结果,但来自地中海发展中国家的此类前瞻性研究却很少。这是一项前瞻性队列研究,于2012年3月至2017年8月在伊拉克库尔德斯坦苏莱曼尼亚市的希瓦癌症医院和埃尔比勒市的纳纳卡利医院进行。分析了成人ALL患者的主要特征、治疗类型和风险因素,以评估它们对治疗结果和生存状况的影响。共纳入109例成人ALL患者,中位年龄为24岁,男女比例为1.7:1。B-ALL占病例的76.1%,其余为T-ALL。12%的B-ALL患者存在BCR-ABL重排。完全缓解(CR)率为81.7%,总体5年生存率(OS)为38%,无复发生存5年生存率(RFS)为49%。与老年组相比,年轻成人(<35岁)的CR率和OS显著更高(均<0.001)。另一方面,性别、白细胞计数≥50×10⁹/L、免疫表型(包括B和T ALL亚型)以及临床风险状态并不能预测不良预后。多变量分析显示,只有年龄<35岁和BCR-ABL重排与更好的OS显著相关。尽管存在一些局限性,但伊拉克成人ALL的治疗结果与西方发达国家报道的结果相当,年轻患者的预后尤其良好。在我国乃至全世界,改善成人ALL治疗结果的需求仍然是一个重要的优先事项。